血液学指标在晚期肺腺癌患者预后中的意义
The Significance of Hematologic Indicators in the Prognosis of Patients with Advanced Lung Adenocarcinoma
摘要: 目的:本研究目的是探索血液学指标在晚期肺腺癌患者预后中的意义,为临床预测患者预后提供依据。方法:收集初次就诊于我院的晚期肺腺癌患者,并收集患者基本信息。用Kaplan Meier法绘制生存曲线,用COX比例风险回归进行单因素及多因素分析。结果:共收集225名晚期肺腺癌患者,通过分析得出纤维蛋白原、LDH与患者的PFS相关,同时也是患者PFS的独立预后因素。纤维蛋白原、NLR与患者的OS相关。结论:纤维蛋白原、LDH是晚期肺腺癌患者PFS的独立因素。
Abstract: Objective: The purpose of this study was to explore the significance of hematologic indicators in the prognosis of patients with advanced lung adenocarcinoma and to provide a basis for clinical prediction of the prognosis of patients. Methods: Patients with advanced lung adenocarcinoma who visited our hospital for the first time were collected, and their basic information was also collected. The survival curve was drawn by Kaplan Meier method, and univariate and multivariate analyses were performed by COX proportional risk regression. Results: A total of 225 patients with advanced lung adenocarcinoma were collected. Through analysis, it was concluded that fibrinogen and LDH were correlated with patients’ PFS and independent prognostic factors of patients’ PFS. Fibrinogen is associated with the patient’s OS. Conclusion: Fibrinogen and LDH are independent factors of PFS in patients with advanced lung adenocarcinoma.
文章引用:王镭蓉, 姜倩倩, 迟晓蕊, 于壮. 血液学指标在晚期肺腺癌患者预后中的意义[J]. 临床医学进展, 2020, 10(5): 828-833. https://doi.org/10.12677/ACM.2020.105127

参考文献

[1] Dela, C.C.S., Tanoue, L.T. and Matthay, R.A. (2011) Lung Cancer: Epidemiology, Etiology, and Prevention. Clinics in Chest Medicine, 32, 605-644. [Google Scholar] [CrossRef] [PubMed]
[2] Calvayrac, O., Pradines, A., Pons, E., et al. (2017) Molecular Biomarkers for Lung Adenocarcinoma. European Respiratory Journal, 49, 10.
[3] Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. [Google Scholar] [CrossRef] [PubMed]
[4] Feng, F., Sun, L., Zheng, G., et al. (2017) Low Lymphocyte-to-White Blood Cell Ratio and High Monocyte-to-White Blood Cell Ratio Predict Poor Prognosis in Gastric Cancer. Oncotarget, 8, 5281-5291. [Google Scholar] [CrossRef] [PubMed]
[5] Feng, F., Tian, Y., Liu, S., et al. (2016) Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors. Medicine, 95, e3248. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, Z., Li, Y., Yan, X., et al. (2019) Pretreatment Lactate Dehydrogenase May Predict Outcome of Advanced Non Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis. Cancer Medicine, 8, 1467-1473. [Google Scholar] [CrossRef] [PubMed]
[7] Sheng, L., Luo, M., Sun, X., et al. (2013) Serum Fibrinogen Is an Independent Prognostic Factor in Operable Nonsmall Cell Lung Cancer. International Journal of Cancer, 133, 2720-2725. [Google Scholar] [CrossRef] [PubMed]
[8] Yu, Y., Qian, L. and Cui, J. (2017) Value of Neutrophil-to-Lymphocyte Ratio for Predicting Lung Cancer Prognosis: A Meta-Analysis of 7,219 Patients. Molecular and Clinical Oncology, 7, 498-506. [Google Scholar] [CrossRef] [PubMed]
[9] Toda, M., Tsukioka, T., Izumi, N., et al. (2018) Platelet-to-Lymphocyte Ratio Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with Surgery and Postoperative Adjuvant Chemotherapy. Thoracic Cancer, 9, 112-119. [Google Scholar] [CrossRef] [PubMed]
[10] Yuan, C., Li, N., Mao, X., et al. (2017) Elevated Pretreatment Neutrophil/White Blood Cell Ratio and Monocyte/Lymphocyte Ratio Predict Poor Survival in Patients with Curatively Resected Non-Small Cell Lung Cancer: Results from a Large Cohort. Thoracic Cancer, 8, 350-358. [Google Scholar] [CrossRef] [PubMed]